Terms: = Leukemia AND CD52, CDW52, EDDM5 AND Treatment
225 results:
1. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
2. cd52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
3. [Chronic neutrophilic leukemia/chronic eosinophilic leukemia].
Kawashima I; Kirito K
Rinsho Ketsueki; 2023; 64(10):1326-1334. PubMed ID: 37914248
[TBL] [Abstract] [Full Text] [Related]
4. Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic leukemia: A Proof-of-Concept Study.
Janker S; Doswald S; Schimmer RR; Schanz U; Stark WJ; Schläpfer M; Beck-Schimmer B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108680
[TBL] [Abstract] [Full Text] [Related]
5. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.
Ottaviano G; Georgiadis C; Gkazi SA; Syed F; Zhan H; Etuk A; Preece R; Chu J; Kubat A; Adams S; Veys P; Vora A; Rao K; Qasim W;
Sci Transl Med; 2022 Oct; 14(668):eabq3010. PubMed ID: 36288281
[TBL] [Abstract] [Full Text] [Related]
6. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
Ma S; Rosen ST; Winqvist M; Frankfurt O; Winter JN; Gordon L; Helenowski I; Zhang H; Kreutzer J; Sönnert-Husa S; Österborg A; Lundin J
Leuk Res; 2022 Nov; 122():106945. PubMed ID: 36115087
[TBL] [Abstract] [Full Text] [Related]
7. [Comparison of the characteristics of NK cells after two different methods of expansion and observation of the clinical efficacy in patients who relapsed post allogeneic hematopoietic stem cell transplantation].
Cao XH; Wang ZD; Sun YQ; Kong J; Lu SY; Tang FF; Zhang YY; Wang JZ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ; Zhao XY
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):400-407. PubMed ID: 35680598
[No Abstract] [Full Text] [Related]
8. Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review.
Pourmontaseri H; Habibzadeh N; Entezari S; Samadian F; Kiyani S; Taheri M; Ahmadi A; Fallahi MS; Sheikhzadeh F; Ansari A; Tamimi A; Deravi N
Hum Antibodies; 2022; 30(3):117-130. PubMed ID: 35662114
[TBL] [Abstract] [Full Text] [Related]
9. An International, Retrospective Study of Off-Label Biologic Use in the treatment of Hypereosinophilic Syndromes.
Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
[TBL] [Abstract] [Full Text] [Related]
10. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.
Furstenau D; Peer CJ; Hughes TE; Uchida N; Tisdale J; Hall OM; Figg WD; Hsieh M
Pharmacotherapy; 2022 Jan; 42(1):14-22. PubMed ID: 34669981
[TBL] [Abstract] [Full Text] [Related]
11. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract] [Full Text] [Related]
12. Mutations in PIGA cause a cd52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract] [Full Text] [Related]
13. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract] [Full Text] [Related]
14. Advances and Perspectives in the treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
Wada M; Zhang H; Fang L; Feng J; Tse CO; Zhang W; Chen Q; Sha S; Cao Y; Chen KH; Pinz KG; Chen X; Fan XX; Jiang X; Ma Y
Stem Cell Rev Rep; 2020 Apr; 16(2):369-384. PubMed ID: 32008159
[TBL] [Abstract] [Full Text] [Related]
16. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract] [Full Text] [Related]
17. Post-transplant lymphoproliferative disorder presenting as T-prolymphocytic leukemia: a case report.
Kasinathan G; Kori AN; Azmie NM
J Med Case Rep; 2019 Jul; 13(1):223. PubMed ID: 31327318
[TBL] [Abstract] [Full Text] [Related]
18. [Successful treatment of T-Cell Prolymphocytic leukemia with Alemtuzumab].
Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
[TBL] [Abstract] [Full Text] [Related]
19. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
McWilliams EM; Lucas CR; Chen T; Harrington BK; Wasmuth R; Campbell A; Rogers KA; Cheney CM; Mo X; Andritsos LA; Awan FT; Woyach J; Carson WE; Butchar J; Tridandapani S; Hertlein E; Castro CE; Muthusamy N; Byrd JC
Blood Adv; 2019 Feb; 3(3):447-460. PubMed ID: 30737226
[TBL] [Abstract] [Full Text] [Related]
20. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
Loeff FC; Rijs K; van Egmond EHM; Zoutman WH; Qiao X; Kroes WGM; Veld SAJ; Griffioen M; Vermeer MH; Neefjes J; Frederik Falkenburg JH; Halkes CJM; Jedema I
Am J Hematol; 2019 Jan; 94(1):93-102. PubMed ID: 30370942
[TBL] [Abstract] [Full Text] [Related]
[Next]
